Baylor Scott & White Medical Center - McKinney
McKinney, Texas, 75071, United States
Location status: Recruiting
Location contact
Arpitha Chiruvolu, MD
SUB_INVESTIGATOR
Karen Stanzo, PhD
CONTACT
Karen Stanzo, PhD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT07217483
Prolact CR (cream) is a fat supplement that is derived from pasteurized human donor milk. It has been utilized in babies who are born premature in the neonatal intensive care unit (NICU) setting to improve growth while avoiding cow milk exposure. There is no literature on the use of cream as a treatment for low blood glucose levels in newborns who are at risk. It is known that fat in human colostrum plays a vital role in providing energy, substrate, and stimulates gluconeogenesis. Gluconeogenesis is the process that helps in the sustainment of blood glucose. Dextrose gel that is used to treat low blood glucose levels helps in raising the blood glucose, but does not help in sustainment.
The objective of this pilot study is to evaluate the utility, feasibility, and acceptability of administering cream for the treatment of newborn low blood glucose levels in a couplet care unit. Investigators hypothesized that 3 ml/kg of cream (0.2 g/kg of carbohydrate and 0.75 g/kg of fat), if given in the place of 0.5 ml/kg (0.2 g/kg of carbohydrate) would increase and stabilize the blood glucose levels. Investigators also speculated that newborns would tolerate the cream with no adverse effects, and caregivers (nurses and parents) would find its use feasible and acceptable.
Parents of newborns with risk factors for hypoglycemia [born to mothers with diabetes, small for gestational age, large for gestational age, or late prematurity (35 to 37 weeks' gestation at birth) who intended to breastfeed exclusively will be approached to consent for the study either before or after delivery of the infant. Newborns with major congenital anomalies or those admitted immediately to the NICU after birth will be excluded.
The main questions hoping to answer
1. What percentage of newborns receiving cream for treatment of hypoglycemia will need NICU admission for IV dextrose? 2. How many median doses of cream are needed? 3. What percentage of infants will be discharge exclusively feeding human milk from couplet care unit? 4. What percentage of the surveys will show parent/nursing satisfaction with the product?
Interested in participating?
Request InfoUp to 24 hour
All sexes
Interventional
Not applicable
McKinney, Texas, 75071, United States
Location status: Recruiting
Arpitha Chiruvolu, MD
SUB_INVESTIGATOR
Karen Stanzo, PhD
CONTACT
Karen Stanzo, PhD
PRINCIPAL_INVESTIGATOR
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Utilizing Prolact CR instead of dextrose gel for management of newborn hypoglycemia
Time frame: Birth to hospital discharge at 2 to 5 days of life
Admission to neonatal intensive care unit for intravenous dextrose for treatment of hypoglycemia
Contact information is provided by the study sponsor or research team.
Arpitha Chiruvolu, MD
CONTACT
Karen Stanzo, PhD
CONTACT
Baylor Research Institute
Other
The Feasibility of Prolacta CR for Treatment of Neonatal Hypoglycemia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06993103
Behavior, Breast Feeding
Brisbane, Queensland, Australia
View Trial DetailsNCT06794307
Female Urogenital Diseases and Pregnancy Complications, Glucose Metabolism Disorders
Aarhus, Central Region Denmark, Denmark
View Trial DetailsNCT04458649
Neonatal Hypoglycemia
La Jolla, California, United States
View Trial DetailsNCT06643351
Diabetes Mellitus, Diabetes, Gestational
Pittsburgh, Pennsylvania, United States
View Trial Details